article

Article: Choosing a CDMO for high potent manufacture

How to select a CDMO partner for the development and commercial manufacture, packaging and launch of products containing highly potent APIs.

Safe handling of highly potent molecules is complex, as are the associated regulatory requirements. To ensure success, pharmaceutical companies must conduct due diligence to identify suitable CDMO partners. In this exclusive supplement, PCI Pharma Services’ Dr Rebecca Coutts discusses the key areas for consideration and best practices when choosing a CDMO for the development, clinical supply, and the commercial manufacture, packaging and launch of drug products containing HPAPIs.